NEUROMETABOLIC DISORDER

A Novel Mutation in PEX11β Gene

How to Cite This Article: Malekzadeh H, Shakiba M^(D), Yasaei M. A Novel Mutation in PEX11β Gene: A Case Report . Iran J Child Neurol. Winter 2021; 15(1): 93-100

Abstract

Hamid MALEKZADEH MD¹,

Marjan SHAKIBA MD¹,

Mehrdad YASAEI MD¹

Department of Pediatric
Endocrinology and
Metabolism, Mofid Children's
Hospital, Shahid Beheshti
University of Medical
Sciences, Tehran, Iran.

Corresponding Author

Shakiba M.MD Department of Pediatric Endocrinology and Metabolism, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Email: shakibamarjan@yahoo. com

Received: 25-Jun-2019 Accepted: 26- Jan-2020 PEX11 β ([OMIM]614920) mutation causes an extremely rare subgroup of peroxisomal biogenesis disorders, with only six cases reported to date. In this article, we reported a patient with episodic migrainelike attacks, delirium, mood and behavior change, polyneuropathy, and history of congenital cataract. Whole exome sequencing showed novel c.743_744delTCinsA mutation in the exon 4 of the PEX11 β gene. In contrast to previously reported patients, our case presented milder features and extended the spectrum of the clinical phenotype of this mutation. This study helps to extend the phenotype of this syndrome; besides, recognizing novel mutation variants will provide a better genotype-phenotype correlation and improve clinical clues.

Keywords: PEX11_β; Peroxisomal Disease; Peroxisome Biogenesis

Disorder; Congenital Cataract

DOI:10.22037/ijcn.v15i1.26129

Introduction

Peroxisomes are membrane-enclosed organelles involved in a variety of metabolic pathways including α - and β -oxidation of fatty acids and synthesis of bile acids, cholesterol, and plasmalogens (1). Mutations in genes encoding peroxisomal proteins are associated with two different groups of peroxisomal disorders: isolated enzyme deficiencies affecting specific metabolic pathways and peroxisome biogenesis disorders (PBDs) causing a defect in the assembly and maintenance of peroxisomes (2). PBDs, including Zellweger spectrum disorders and rhizomelic chondrodysplasia punctuate, are mainly caused by mutations in PEX proteins. These proteins, also known as peroxins, are encoded by 16 different PEX genes (3). The phenotypic presentation can range from mild to severe and early to late due to genetic heterogeneity (2).

PEX11 family members encode peroxisomal membrane proteins which coordinate peroxisome proliferation and maintenance and have a direct role in the metabolism of fatty acids (4, 5). Among PEX11 gene subgroups, recently, six patients have been reported to have PEX11 β mutations ([OMIM] 614920) with various clinical presentations. In this article, we reported a patient with a novel mutation in the PEX11 β gene and new clinical features.

Case Report

A 15-year-old boy was referred to our hospital with presenting symptoms of nausea, vomiting, severe headache, delirium, and a complaint of mood and behavior change. He was the first child of consanguineous parents born at term with a birth weight of 3.1 kg. He had no history of intellectual disability, but a mild motor developmental delay was reported in his past medical history; he started walking at 18 months. He was diagnosed with bilateral cataracts at birth and underwent surgery in his 40 days of life, but no further workup was performed at that time. When he was 2.5 years old, he experienced three episodes of clonic seizure attacks during one month; however, EEG and MRI did not show abnormalities at that time. He did not experience any symptoms until 11 years of age when an episode of fever, confusion, and delirium occurred. CBC, blood biochemistry, lumbar puncture analysis, and brain MRI were all normal at that time, and a diagnoses of viral encephalitis was made. He experienced similar episodes at

the age of 13. His parents stated that he exhibited behavioral and emotional problems like childish talk and mood instability during the attacks and turned normal after the episodes terminated. He also experienced headaches with migraine-like features during these episodes. The episodes resolved spontaneously within two weeks, and no specific trigger was noted.

Upon physical examination, he was disoriented to time and place. He exhibited delirious state and childish behaviors like engaging in baby talk and short attention spans. He had a mild dry skin, mostly visible on the extremities and his face. Moreover, he had an abnormal gait and neurologic examination detected normal muscle tone and strength but reduced symmetrical reflexes in lower extremities. No significant abnormalities were found in other examinations.

Initial blood tests of the patient were within normal limits, and his liver function tests, lipid profile, ammonia, and lactate showed no abnormality. Further, no pathologic results were found in primary metabolic screening for fatty acid oxidation disorders, organic acidemias, and amino acid disorders. Urine organic acids and homocysteine levels as well as plasma amino acids levels measured with high performance liquid chromatography were normal. Moreover, plasma levels of very-long-chain fatty acids (C26:0, C24:0/C22:0, and C26:0/C22:0) and pristanic and phytanic acids revealed no abnormalities. The auditory brainstem response test was performed, and no defects were reported. On the other hand, the nerve conduction velocity test revealed both sensory and motor polyneuropathy bilaterally in lower extremities.

With suspicion to mitochondrial or peroxisomal disorders, the mitochondrial treatment protocol (Vit B1, Vit B2, CoQ10, Vit E, b6, and L-carnitine selenium) was administered for the patient. The attack resolved in days with no significant clinical damage.

Whole exome sequencing was requested due to the patient's clinical features. DNA extracted from his blood was used to perform targeted gene capture using a custom capture kit. The obtained sequences were aligned to human reference genome (GRCh37/hg19) using the BWA program (6, 7) and analyzed using the Picard and GATK-Lite toolkit. The result indicated that the novel c.743_744delTCinsA mutation was located in the exon 4 of the PEX11B gene, leading to a frameshift and premature truncation of three amino acids downstream to the codon 248 (p.Leu248GInfsTer3). Sanger sequencing confirmed that the patient was homozygous for this variant. This novel variant was predicted to be damaging by Mutation Taster and considered as a pathogenic variant mutation of the disease.

Table 1. Summary of phenotypic features of the reported cases of PEX11 β mutations	presented	15 y / Male		Normal	Reduced	Normal	Seizures, Migraine- like episodes with confusion and delirium		+	ı		ı
	Taylor et al. (v)	23 mo. / Female		Normal	Normal	Normal			+	ı		+
	Taylor et al. (iv)	35 mo. / Male		Hypotonia	Normal	Conductive HL	Seizures		+			+
	Taylor et al. (iii)	6 y / Female		Hypotonia	Increased	Normal	Reduced muscular strength, Four-limb spasticity		+	Aphakic gkaucoma		+
	Taylor et al. (ii)	6 y / Male		Normal	Normal	Sensorineural HL	Reduced muscular strength		+	Aphakic gkaucoma, Phtiasis		+
	Taylor et al. (i)	23 y / Female		Normal	Reduced	Normal	Nystagmus, Nonreactive pupils		+	Divergent strabismus, Microphtalmia		+
	Ebberink et al.	26 y / Male		Normal	Reduced	Perceptive HL*	Migraine- like episodes, Sensory disturbance, nystagmus		+			+
		Age / Sex	Neurologic	Muscular tone	Reflexes	Hearing	Other	Eyes	Bilateral congenital Cataract	Other	Development	Intellectual disability

Normal / 18 mo.		Behavioral & emotional problems	Dry skin	
Normal / Normal	Normal	Behavioral problems, Poor concentration	1	
Normal / 16 mo.	18 mo.	Delayed fine motor skills	FTT, High forehead	
2 y / -	2 y	Behavioral problems	FTT, Scoliosis, Dry skin	
1 y / 2 y	2 y	Regression following trauma, Behavioral & emotional problems	Short stature, Flat feet with hallux valgus, Dry skin, GI problems	
Normal / Normal	Normal		Short stature, flat feet with hallux valgus, dry skin, GI† problems	
Normal / 1.5 y	Normal	Regression following surgery	Dry, scaly skin	•
Sitting / walking	Speech	Other	Other systems	

*Hearing Loss, † Gastrointestinal

Table 1. (continuous)

Discussion

PBDs are a group of genetic inborn errors of metabolism, in which defective biogenesis of peroxisomes leads to complex clinical and metabolic phenotypes. Peroxisome biogenesis is controlled by proteins that encompass processes involved in the control of peroxisome size and number, and other proteins intervene in the assembly of matrix and membrane proteins on peroxisomes (8). Proteins involved in these processes are peroxins encoded by PEX genes, and dysfunction in 14 identical peroxins are associated with human diseases. PEX11 β which was first linked to human disease in 2012 plays a role in peroxisome division and membrane elongation (9-11).

In 2012, Ebberink et al. reported the first patient with a homozygous nonsense mutation in the PEX11 β gene. The patient was a 26-year-old Dutchman of non-consanguineous parents, presenting with a history of congenital cataract, mild intellectual disability, bilateral progressive hearing loss, gastrointestinal problems, polyneuropathy, and recurrent migraine-like episodes (12). In 2016, Taylor et al. described five individuals with novel biallelic loss of function mutations in the PEX11B gene from three different families. They were presented with congenital cataract, intellectual disability, seizure, hearing loss, gastrointestinal complaints, behavioral problems, and dry skin. Moreover, skeletal involvements and short stature were observed in some cases (Table 1).

Episodic migraine-like attacks presented in our patient were similar to those in a case reported by Ebberink et al. (12). Although periodic mood change with childish behavior during attacks may be classified as a spectrum of behavioral disturbances observed in previous PEX11 β mutations, it should be noted that the periodic and resolving aspects of this feature were unique in our case. Polyneuropathy, which was shown in the first reported case, was demonstrated with milder symptoms in our patient. Hearing loss, as well as abnormal mental development, gastrointestinal complaints, and skeletal disorders were not developed in our case. History of bilateral congenital cataract was present in all of the reported patients, suggesting PBDs to be considered among differential diagnoses for congenital cataract (13). Congenital cataract is inherited in both autosomal dominant and recessive fashions and affects 2.5 to 3.5 per 10000 births. Determining the genetic cause of congenital cataract could have significant clinical relevance by guiding genetic counseling and implementing early treatment strategies (14).

For many hereditary genetic disorders, disease severity is determined by the type of mutation and its impact on protein function. The milder phenotype in this patient suggests that the type and location of mutation in the PEX11 β gene may be associated with the severity and divergence of symptoms. The novel mutation described in this article has not been reported previously. The consanguinity of parents is compatible with autosomal recessive inheritance described for this syndrome (13). Our findings expanded the spectrum and severity of the clinical phenotype associated with PEX11 β variants. We also showed that PBDs could exist despite normal biochemical measurements, highlighting genetic analysis as an appropriate means for diagnosis of PEX11 β variants when there is a high suspicion for presence of a systemic metabolic disease.

Because of the rarity of this disease, no treatment protocol has been established yet. Administering L-carnitine and the Co-Q10 enzyme in the first reported patient showed an overall improvement in his condition, although he still experiences migraine-like attacks (12). In our patient, a mitochondrial treatment protocol was initiated in the last attack; however, it was discontinued after the symptoms resolved.

In Conclusion

PEX11 β mutation causes an extremely rare subgroup of peroxisomal biogenesis disorders, with only seven cases reported to date. The main feature of the disease is congenital cataract that was developed in all of the reported cases. Normal metabolic tests in our case drew attention to the utility of genetic analysis when presence of a systemic metabolic disorder is likely. Extending the phenotype of this syndrome in addition to recognizing novel mutation variants will provide a better genotype-phenotype correlation and enhance clinical diagnostic clues.

Acknowledgment

We would like to thank family members for their participation. The authors also thank Dr. Kasra Molooghi for his help in English editing of the manuscript.

Author's Contribution

Marjan Shakiba visited the patient at the office and hospital ward and planed his diagnostic and treatment approach. Hamid Malekzadeh and Mehrdad Yasaei did the literature review and wrote the first draft of the manuscript. Hamid Malekzadeh, Marjan Shakiba and Mehrdad Yasaei contributed to the manuscript writing and revising it critically for important intellectual content. Authors give final approval of the version to be submitted. Marjan Shakiba is the guarantor for the article and accepts full responsibility for the work.

Conflict of interest

the authors whose names are listed below certify that they have not accepted any reimbursement for attending a symposium, funds for research or for member of staff or any fee for speaking, organizing education or consulting that relate the issue of this article. Also they have not been employed in any organization that may gain or lose financially from this article.

References

- 1. Wanders RJ, Waterham HR. Biochemistry of mammalian peroxisomes revisited. Annual review of biochemistry. 2006;75:295-332.
- Steinberg SJ, Dodt G, Raymond GV, Braverman NE, Moser AB, Moser HW. Peroxisome biogenesis disorders. Biochimica et biophysica acta. 2006;1763(12):1733-48.
- Smith JJ, Aitchison JD. Peroxisomes take shape. Nature reviews Molecular cell biology. 2013;14(12):803-17.
- Koch J, Pranjic K, Huber A, Ellinger A, Hartig A, Kragler F, et al. PEX11 family members are membrane elongation factors that coordinate peroxisome proliferation and maintenance. Journal of cell science. 2010;123(Pt 19):3389-400.
- Li X, Gould SJ. PEX11 promotes peroxisome division independently of peroxisome metabolism. The Journal of cell biology. 2002;156(4):643-51.
- Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics (Oxford, England). 2009;25(14):1754-60.
- Meyer LR, Zweig AS, Hinrichs AS, Karolchik D, Kuhn RM, Wong M, et al. The UCSC Genome Browser database: extensions and updates

2013. Nucleic acids research. 2013;41(Database issue):D64-9.

- Yan M, Rayapuram N, Subramani S. The control of peroxisome number and size during division and proliferation. Current opinion in cell biology. 2005;17(4):376-83.
- Waterham HR, Ebberink MS. Genetics and molecular basis of human peroxisome biogenesis disorders. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2012;1822(9):1430-41.
- Braverman NE, D'agostino MD, MacLean GE. Peroxisome biogenesis disorders: Biological, clinical and pathophysiological perspectives. Developmental disabilities research reviews. 2013;17(3):187-96.
- Fujiki Y. Peroxisome biogenesis and human peroxisome-deficiency disorders. Proceedings of the Japan Academy, Series B. 2016;92(10):463-77.

- Ebberink MS, Koster J, Visser G, van Spronsen F, Stolte-Dijkstra I, Smit GPA, et al. A novel defect of peroxisome division due to a homozygous non-sense mutation in the PEX11β gene. Journal of medical genetics. 2012;49(5):307-13.
- 13. Taylor RL, Handley MT, Waller S, Campbell C, Urquhart J, Meynert AM, et al. Novel PEX11B mutations extend the peroxisome biogenesis disorder 14B phenotypic spectrum and underscore congenital cataract as an early feature. Investigative ophthalmology & visual science. 2017;58(1):594-603.
- 14. Gillespie RL, O'Sullivan J, Ashworth J, Bhaskar S, Williams S, Biswas S, et al. Personalized diagnosis and management of congenital cataract by next-generation sequencing. Ophthalmology. 2014;121(11):2124-37.e1-2.